Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HLX 43

Next Previous
Drug Profile

HLX 43

Alternative Names: Anti-PD-L1 ADC; HLX-43

Latest Information Update: 26 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Henlius Biotech
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thymic epithelial tumour
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Cervical cancer; Colorectal cancer; Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Squamous cell cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 26 Mar 2026 Shanghai Henlius Biotech plans a phase II trial in Triple negative breast cancer (Late-stage disease, Recurrent, Metastatic disease, Monotherapy, Combination Therapy, Unresectable/Inoperable) in China (Parenteral) (NCT07487519)
  • 10 Mar 2026 Shanghai Henlius Biotech plans a phase II trial for HER2-negative breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in April 2026 (IV) (NCT07459738)
  • 05 Mar 2026 Shanghai Henlius Biotech plans a phase II/III trial for Non-small cell lung cancer (Monotherapy, Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in China(IV) in April 2026 (NCT07459751)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top